ODTX Odyssey Therapeutics, Inc.

MIXED Impact: 6/10 EFFECT
Horizon immediate Filed May 8, 2026 Processed 1mo ago SEC 9999999995-26-001538
IPO/offering going effective
Latest settled — T+20d ⚠ clustered
ODTX ▲ +0.06% at T+20d
NEUTRAL call ✓ call won +0.06% · α vs SPY +0.04% · entry $16.42 → $16.43
Next anchor: T+60d in 7w
Currently $16.90 · +2.92% from $16.42 entry
Entry anchored
May 8, 2026
via day open
T+1d
+6.27%
call +6.27% · α +6.04%
$17.45
settled 5w ago
T+5d
+5.48%
call +5.48% · α +4.02%
$17.32
settled 29d ago
T+20d
+0.06%
call +0.06% · α +0.04%
$16.43
settled 5d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Odyssey Therapeutics' IPO registration (S-1) became effective on May 7, 2026, clearing the final regulatory hurdle for the company to begin trading on Nasdaq under ticker ODTX. The offering is set at 13.24M shares (plus greenshoe) at $16-$18, with a concurrent $25M private placement. The company is a pre-revenue clinical-stage biopharma with a going concern qualification, making this a high-risk IPO.

Actionable Insight

IPO pricing likely within 1-2 days. The $16-$18 range implies a market cap of roughly $800M-$900M at IPO. Watch for final pricing and first-day trading performance. The going concern qualification and pre-revenue status suggest high volatility post-listing.

Key Facts

  • IPO registration declared effective on May 7, 2026
  • Offering: 13.24M shares (plus greenshoe) at $16-$18 per share
  • Concurrent $25M private placement
  • Company is pre-revenue with $148.6M net loss in 2025
  • Going concern qualification noted in S-1/A
  • Positive Phase 2a data for lead candidate OD-001 in ulcerative colitis
  • Listing on Nasdaq Capital Market under ticker ODTX

Financial Impact

IPO expected to raise approximately $212M-$238M (assuming mid-point pricing and full greenshoe) plus $25M private placement, totaling ~$237M-$263M gross proceeds

cashdilutionmarket cap

Risk Factors

  • Pre-revenue with substantial losses and going concern qualification
  • Clinical-stage risk: OD-001 still in Phase 2a, no approved products
  • IPO pricing may be adjusted downward if market conditions weaken
  • Dilution from 13.24M share offering plus greenshoe and private placement

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001538
Document: 9999999995-26-001538-index.html9999999995-26-001538
Document: 9999999995-26-001538.txt9999999995-26-001538
15 reports for ODTX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+1▲ +6.27%May 8, 2026
Filters
Rows
Reports for ODTX — sortable, filterable
Type Now
May 11, 2026
4w ago
Insider Cluster
BULLISH ★ 7/10
$17.45 $17.39▼ −0.34%▼ −0.26%$16.90 (−3.15%)
May 8, 2026
5w ago
424B4
MIXED ★ 6/10
$17.45 $17.39▼ −0.34%▼ −0.26%$16.90 (−3.15%)
May 8, 2026
5w ago
EFFECT
MIXED ★ 6/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 2/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 2/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 2/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 2/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 2/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 2/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
May 8, 2026
5w ago
3
NEUTRAL ★ 1/10
$16.42 $17.32▲ +5.48%▲ +4.02%$16.90 (+2.92%)
Showing 10 of 15

US Market Status

Market Closed — Opens Mon (49h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access